Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus.

Literature DB >> 6818899

In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus.

M Díez Enciso, M Mateos Lindemann, A Gutiérrez Altés.

Abstract

The in vitro synergistic activity of N-formimidoyl thienamycin and amikacin was determined against gentamicin-resistant enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus. N-Formimidoyl thienamycin showed synergism with amikacin against 19 of the gentamicin-resistant strains, 14 of the 49 strains of S. aureus, and only 1 strain of the 46 P. aeruginosa isolates.

Entities: Chemical Species

Mesh：

Substances：

Year: 1982 PMID： 6818899 PMCID： PMC185722 DOI： 10.1128/AAC.22.6.1064

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Antibiotic combinations: the clinical relevance of synergy and antagonism.

Authors: J J Rahal
Journal: Medicine (Baltimore) Date: 1978-03 Impact factor: 1.889

2. Comparison of techniques for measurement of in vitro antibiotic synergism.

Authors: C W Norden; H Wentzel; E Keleti
Journal: J Infect Dis Date: 1979-10 Impact factor: 5.226

3. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors: H C Neu; P Labthavikul
Journal: Antimicrob Agents Chemother Date: 1982-01 Impact factor: 5.191

4. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

Authors: J S Kahan; F M Kahan; R Goegelman; S A Currie; M Jackson; E O Stapley; T W Miller; A K Miller; D Hendlin; S Mochales; S Hernandez; H B Woodruff; J Birnbaum
Journal: J Antibiot (Tokyo) Date: 1979-01 Impact factor: 2.649

5. Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12.

Authors: B G Spratt; V Jobanputra; W Zimmermann
Journal: Antimicrob Agents Chemother Date: 1977-09 Impact factor: 5.191

6. Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains.

Authors: M Toda; K Sato; H Nakazawa; M Inoue; S Mitsuhashi
Journal: Antimicrob Agents Chemother Date: 1980-11 Impact factor: 5.191

7. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors: C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal: Antimicrob Agents Chemother Date: 1972-04 Impact factor: 5.191

8. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors: H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal: Antimicrob Agents Chemother Date: 1980-06 Impact factor: 5.191

9. In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors: F P Tally; N V Jacobus; S L Gorbach
Journal: Antimicrob Agents Chemother Date: 1980-10 Impact factor: 5.191

10. In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors: V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal: Antimicrob Agents Chemother Date: 1980-10 Impact factor: 5.191

8 in total

1. In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.

Authors: M Díez Enciso
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-02 Impact factor: 3.267

2. In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors: E Debbia; P E Varaldo; G C Schito
Journal: Antimicrob Agents Chemother Date: 1986-11 Impact factor: 5.191

3. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.

Authors: C I Bustamante; G L Drusano; R C Wharton; J C Wade
Journal: Antimicrob Agents Chemother Date: 1987-04 Impact factor: 5.191

Review 4. In vitro activity of imipenem--a review.

Authors: I Braveny
Journal: Eur J Clin Microbiol Date: 1984-10 Impact factor: 3.267

Review 5. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors: S P Clissold; P A Todd; D M Campoli-Richards
Journal: Drugs Date: 1987-03 Impact factor: 9.546

6. Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections.

Authors: W Fan; R del Busto; M Love; N Markowitz; C Cendrowski; J Cardenas; E Quinn; L Saravolatz
Journal: Antimicrob Agents Chemother Date: 1986-01 Impact factor: 5.191

7. Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.

Authors: T M Hooton; A D Blair; M Turck; G W Counts
Journal: Antimicrob Agents Chemother Date: 1984-10 Impact factor: 5.191

8. [Dosage of imipenem/cilastatin].

Authors: P M Shah
Journal: Infection Date: 1986 Impact factor: 3.553

8 in total